Biotech company Bristol Myers Squibb (BMY) just connected its cancer franchise to Microsoft’s (MSFT) AI radiology stack to spot lung cancer earlier.

The Wegovy pill launch just reminded the market that health-tech company Novo Nordisk (NVO) still runs the obesity drug game. Early prescriptions for the Wegovy pill hit hard and Wall Street noticed.

2026 is shaping up to be the year of obesity pills in the health-tech market, and we don’t think that’s hype. We think it marks a real shift in how weight-loss medicine fits into everyday life. 

OpenAI has acquired health-tech startup Torch, the company said Monday. The acquisition marks an important step in their AI health assistant development. 

Health tech company AbbVie (ABBV) said on Wednesday it plans to build a larger presence in the fast-growing obesity drug market, focusing on treatments designed to be easier for patients.

Nvidia and U.S. drugmaker Eli Lilly said they will spend $1 billion over five years to build a joint AI research lab in the San Francisco Bay Area.

CES 2026 had plenty of flashy ideas, but three products stood out because they point to real changes in the fields of AI, Robotics, and Health tech. 

Health tech company Eli Lilly (LLY) said it will acquire autoimmune drug developer Ventyx Biosciences (VTYX) for $1.2 billion in cash, expanding its research pipeline.

The biggest AI company OpenAI on Wednesday announced the launch of ChatGPT Health, a new experience designed to let users securely connect medical records and wellness apps to its chatbot.

Health tech company Novo Nordisk (NVO) began rolling out the first GLP-1 pill for obesity in the U.S. on Monday. The launch marks the first oral option in a market long dominated by weekly injections.

Elon Musk said his biotech company Neuralink plans to begin high-volume production of its devices in 2026. He also said the company aims to shift to a fully automated surgical procedure in the same year.

Biotech stock Ultragenyx Pharmaceutical Inc (RARE) plunged on Monday after the company said late-stage trials of its bone disease drug failed to meet the main study goal.

Shares of Agios Pharmaceuticals Inc (AGIO) rose nearly 16% on Wednesday after U.S. regulators approved an expanded use of the company’s blood disorder drug.

Cytokinetics Inc. (CYTK) has secured US approval for its first commercial medicine, setting up direct competition with a key heart drug sold by Bristol Myers Squibb Co. (BMY).

Shares in Novo Nordisk (NVO) rose sharply Tuesday after U.S. regulators approved the company’s GLP-1 pill, marking a first for the drug class.

BioMarin Pharmaceutical Inc. (BMRN) agreed to acquire Amicus Therapeutics Inc. (FOLD) for about $4.8 billion in cash. The deal expands BioMarin’s portfolio of treatments for rare diseases.

Xanadu Quantum Technologies Inc. has developed a quantum computational framework aimed at accelerating the discovery of next-generation photosensitizers for photodynamic cancer therapy.

Takeda Pharmaceutical Co (TAK) said its experimental oral treatment for plaque psoriasis met its main goals in two late-stage clinical studies.

Eli Lilly (LLY) said Thursday that its experimental obesity pill helped patients maintain most of their prior weight loss after switching from injectable treatments in a late-stage trial.

The U.S. Food and Drug Administration has approved AstraZeneca (AZN) and Daiichi Sankyo’s breast cancer drug Enhertu for use as a first-line treatment, the agency said on Monday.